Investigational Drug Details
| Drug ID: | D328 |
| Drug Name: | Serine |
| Synonyms: | (S)-2-Amino-3-hydroxypropanoic acid; (S)-Serine; alpha-Amino-beta-hydroxypropionic acid; beta-Hydroxyalanine; L-Serine; Ser; Serine |
| Type: | Chemical drug |
| DrugBank ID: | DB00133 |
| DrugBank Description: | A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from glycine or threonine. It is involved in the biosynthesis of purines; pyrimidines; and other amino acids. |
| PubChem ID: | 5951 |
| CasNo: | 302-84-1 |
| Repositioning for NAFLD: | No |
| SMILES: | C(C(=O)O)(CO)N |
| Structure: |
|
| InChiKey: | MTCFGRXMJLQNBG-UHFFFAOYSA-N |
| Molecular Weight: | 105.093 |
| DrugBank Targets: | Cystathionine beta-synthase; L-serine dehydratase/L-threonine deaminase; Serine racemase; Serine palmitoyltransferase 2; Serine palmitoyltransferase 1; Serine--tRNA ligase, cytoplasmic; Serine--pyruvate aminotransferase |
| DrugBank MoA: | L-Serine plays a role in cell growth and development (cellular proliferation). The conversion of L-serine to glycine by serine hydroxymethyltransferase results in the formation of the one-carbon units necessary for the synthesis of the purine bases, adenine and guanine. These bases when linked to the phosphate ester of pentose sugars are essential components of DNA and RNA and the end products of energy producing metabolic pathways, ATP and GTP. In addition, L-serine conversion to glycine via this same enzyme provides the one-carbon units necessary for production of the pyrimidine nucleotide, deoxythymidine monophosphate, also an essential component of DNA. |
| DrugBank Pharmacology: | Serine is classified as a nutritionally non-essential amino acid. Serine is critical for the production of the body's proteins, enzymes and muscle tissue. Serine is needed for the proper metabolism of fats and fatty acids. It also helps in the production of antibodies. Serine is used as a natural moisturizing agent in some cosmetics and skin care products. The main source of essential amino acids is from the diet, non-essential amino acids are normally synthesize by humans and other mammals from common intermediates. |
| DrugBank Indication: | Used as a natural moisturizing agent in some cosmetics and skin care products. |
| Targets: | SRR |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Phase 1&2 completed (NCT02599038) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0859 | NCT02599038 | Phase 1/Phase 2 | Not recruiting | No Results Available | 03/11/2015 | 24 October 2016 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00006 | 35256934 | Acta Pharm Sin B | Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. | Details |
| A00100 | 35220131 | Phytomedicine | 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside ameliorates NAFLD via attenuating hepatic steatosis through inhibiting mitochondrial dysfunction dependent on SIRT5. | Details |
| A00141 | 35212227 | J Agric Food Chem | Targeted Lipidomics Reveal the Effects of Different Phospholipids on the Phospholipid Profiles of Hepatic Mitochondria and Endoplasmic Reticulum in High-Fat/High-Fructose-Diet-Induced Nonalcoholic Fatty Liver Disease Mice. | Details |
| A00217 | 35181350 | Diabetes Res Clin Pract | Metabolic Changes Induced by Dapagliflozin, an SGLT2 Inhibitor, in Japanese Patients with Type 2 Diabetes Treated by Oral Anti-diabetic Agents: A Randomized, Clinical Trial. | Details |
| A00260 | 35162992 | Int J Mol Sci | Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. | Details |
| A00342 | 35127372 | Acta Pharm Sin B | The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy. | Details |
| A00343 | 35127371 | Acta Pharm Sin B | Therapeutic regulation of autophagy in hepatic metabolism. | Details |
| A00458 | 35074921 | Proc Natl Acad Sci U S A | Myeloid cell TBK1 restricts inflammatory responses. | Details |
| A00464 | 35070304 | Mol Clin Oncol | Serine palmitoyltransferase long chain subunit 3 is associated with hepatocellular carcinoma in patients with NAFLD. | Details |
| A00728 | 34986838 | Cancer Cell Int | STK25 enhances hepatocellular carcinoma progression through the STRN/AMPK/ACC1 pathway. | Details |
| A00832 | 34954499 | Redox Biol | Inhibition of GCN2 alleviates hepatic steatosis and oxidative stress in obese mice: Involvement of NRF2 regulation. | Details |
| A01134 | 34859513 | Phytother Res | Scutellarin ameliorates hepatic lipid accumulation by enhancing autophagy and suppressing IRE1α/XBP1 pathway. | Details |
| A01198 | 34830360 | Int J Mol Sci | Time-Dependent Changes in Hepatic Sphingolipid Accumulation and PI3K/Akt/mTOR Signaling Pathway in a Rat Model of NAFLD. | Details |
| A01279 | 34803916 | Front Endocrinol (Lausanne) | Sestrin2 as a Potential Target for Regulating Metabolic-Related Diseases. | Details |
| A01444 | 34743657 | Adipocyte | Association of cell death mechanisms and fibrosis in visceral white adipose tissue with pathological alterations in the liver of morbidly obese patients with NAFLD. | Details |
| A01446 | 34742934 | Arch Biochem Biophys | The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids. | Details |
| A01555 | 34695228 | Eur J Clin Invest | Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis. | Details |
| A01608 | 34680557 | Biomedicines | Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet. | Details |
| A01794 | 34614409 | Cell Metab | DRAK2 aggravates nonalcoholic fatty liver disease progression through SRSF6-associated RNA alternative splicing. | Details |
| A01815 | 34606548 | Food Funct | Sesamol supplementation alleviates nonalcoholic steatohepatitis and atherosclerosis in high-fat, high carbohydrate and high-cholesterol diet-fed rats. | Details |